Cancer Biopsy Market Outlook:
Cancer Biopsy Market size was over USD 29.73 billion in 2025 and is poised to exceed USD 65.38 billion by 2035, witnessing over 8.2% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of cancer biopsy is estimated at USD 31.92 billion.
Key drivers include increasing demand for minimally invasive procedures, the development of liquid biopsies, and the integration of molecular diagnostics that enable personalized treatment plans. Factors such as growing awareness of early cancer detection and supportive government initiatives for cancer screening are further fueling the market expansion.
For instance, as per the U.S. Embassy and Consulates, in September 2024, the U.S. Australia, India, and Japan announced the launch of the Quad Cancer Moonshot to strengthen the overall cancer care ecosystem in the Indo-Pacific. It aims to improve health infrastructure, expand research collaborations, build data systems, and provide greater support for the prevention, detection, treatment, and post-treatment care of cancer. As per the National Cancer Institute, new cancer cases per year are projected to reach 29.9 million, leading to 15.3 million cancer-related deaths, worldwide. Owing to these rising cases and advancements in therapies, the global cancer biopsy market is projected to witness a significant rise during the forecast period.
